MCID: NRC002
MIFTS: 62

Narcolepsy malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Narcolepsy

About this section
Sources:
11Disease Ontology, 13DISEASES, 25Genetics Home Reference, 26GTR, 29ICD10, 30ICD10 via Orphanet, 31ICD9CM, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 48NINDS, 49Novoseek, 53Orphanet, 61SNOMED-CT, 67UMLS, 68UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Narcolepsy:

Name: Narcolepsy 11 47 25 48 49 38 13 67
Narcolepsy-Cataplexy Syndrome 47 53 26 67
Narcoleptic Syndrome 47 25
Gelineau Syndrome 47 25
Paroxysmal Sleep 11 47
 
Narcolepsy, Without Cataplexy 11
Narcolepsy Without Cataplexy 53
Gelineau's Syndrome 47
Gélineau Disease 53

Characteristics:

Orphanet epidemiological data:

53
narcolepsy-cataplexy syndrome:
Prevalence: 1-5/10000 (Europe),1-5/10000 (Norway),1-5/10000 (Finland),1-5/10000 (China); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy
narcolepsy without cataplexy:
Prevalence: 1-5/10000 (United States); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:8986
ICD9CM31 347.0
MeSH38 D009290
NCIt44 C84489
ICD10 via Orphanet30 G47.4
MESH via Orphanet39 D009290
UMLS via Orphanet68 C0027404, C0751362

Summaries for Narcolepsy

About this section
NINDS:48 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles normally. At various times throughout the day, people with narcolepsy experience irresistable bouts of

MalaCards based summary: Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to narcolepsy 1 and cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, and has symptoms including hallucinations, muscle weakness and memory impairment. An important gene associated with Narcolepsy is HCRT (Hypocretin Neuropeptide Precursor), and among its related pathways are Translocation of ZAP-70 to Immunological synapse and CTLA4 Signaling. The drugs amphetamine adipate and dextroamphetamine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related mouse phenotypes are behavior/neurological and nervous system.

Disease Ontology:11 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

Genetics Home Reference:25 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.

Wikipedia:70 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

About this section

Diseases in the Narcolepsy family:

Narcolepsy 2 Narcolepsy 7
Narcolepsy 5 Narcolepsy 1
Narcolepsy 6 Narcolepsy 3
Narcolepsy 4 Narcolepsy Risk Factor

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 134)
idRelated DiseaseScoreTop Affiliating Genes
1narcolepsy 112.4
2cerebellar ataxia, deafness, and narcolepsy, autosomal dominant12.2
3narcolepsy 712.2
4narcolepsy 211.9
5narcolepsy 311.8
6narcolepsy 511.8
7narcolepsy 611.8
8narcolepsy 411.8
9narcolepsy risk factor11.7
10hypersomnia11.3
11idiopathic hypersomnia11.2
12sleep disorder11.2
13idiopathic juxtafoveal retinal telangiectasia11.0HCRT, HLA-DQB1
14osteogenesis imperfecta congenita, microcephaly, and cataracts10.9HLA-DQA1, HLA-DQB1
15krieble bixler syndrome10.9HLA-DQB1, HLA-DRB1, TNF
16wolffian duct adenocarcinoma10.9HLA-DQA1, HLA-DQB1, HLA-DRB1
17lymphocytic colitis10.9HLA-DQB1, HLA-DRB1, TNF
18peripheral t-cell lymphoma10.9HLA-DQB1, HLA-DRB1, TNF
19lipodermatosclerosis10.9HLA-DQB1, HLA-DRB1, TNF
20autoinflammation, lipodystrophy, and dermatosis syndrome10.9HLA-DQA1, HLA-DQB1, HLA-DRB1
21idiopathic central precocious puberty10.9HLA-DQB1, HLA-DRB1, TNF
22panuveitis10.9HLA-DQA1, HLA-DRB1, TNF
23aseptic osteitis10.9HLA-DQA1, HLA-DQB1, HLA-DRB1
24glutathionuria10.9COMT, HCRT, HLA-DQB1
25sensorineural hearing loss10.9HLA-DQB1, HLA-DRB1, TNF
26newborn respiratory distress syndrome10.9HCRT, HLA-DRB1, MOG
27fruit allergy10.9HLA-DQB1, HLA-DRB1
28oculogyric crisis10.9HLA-DQA1, HLA-DQB1, HLA-DRB1
29quinquaud's decalvans folliculitis10.9HLA-DQB1, HLA-DRB1
30allergic hypersensitivity disease10.9HLA-DQB1, HLA-DRB1, TNF
31multicentric castleman disease10.9HLA-DQA1, HLA-DQB1, HLA-DRB1
32bullous retinoschisis10.9HCRT, HLA-DRB1, MOG, TNF
33ampulla of vater neoplasm10.9HLA-DQA1, HLA-DQB1, TNF
34breast carcinoma in situ10.9HLA-DQB1, HLA-DRB1, MOG, TNF
35ovarian papillary cystadenoma10.9HLA-DQA1, HLA-DQB1, HLA-DRB1, MOG
36measles10.9COMT, HCRT, HLA-DQB1
37parsonage turner syndrome10.9HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
38myopathy-growth delay-intellectual disability-hypospadias syndrome10.9HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
39hypoxia10.9HCRT, HCRTR1, HLA-DQB1, HLA-DRB1
40achilles bursitis10.9HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
41common variable immunodeficiency10.9HLA-DRB1, TNF
42bile duct signet ring cell carcinoma10.9HLA-DQA1, HLA-DRB1, TNF
43renovascular hypertension10.9HLA-DQA1, HLA-DRB1, TNF
44hereditary neuropathies10.9HCRTR2, HLA-DQB1, TNF
45pediatric systemic lupus erythematosus10.9HLA-DQB1, HLA-DRB1
46kernicterus10.9HLA-DRB1, MOG, TNF
47weber syndrome10.9HLA-DRB1, TNF
48lethal midline granuloma10.9HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
49sternum lymphoma10.8HLA-DQA1, HLA-DRB1, TNF
50hemophagocytic lymphohistiocytosis, familial, 510.8DNMT1, HCRT

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, EssentialHypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to narcolepsy

Symptoms for Narcolepsy

About this section

Human phenotypes related to Narcolepsy:

 63 53 (show all 20)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hallucinations63 53 hallmark (90%) Very frequent (99-80%) HP:0000738
2 muscle weakness63 hallmark (90%) HP:0001324
3 memory impairment63 hallmark (90%) HP:0002354
4 sleep disturbance63 53 hallmark (90%) Very frequent (99-80%) HP:0002360
5 reduced consciousness/confusion63 hallmark (90%) HP:0004372
6 abnormality of eye movement63 typical (50%) HP:0000496
7 obesity63 53 occasional (7.5%) Occasional (29-5%) HP:0001513
8 sudden cardiac death63 occasional (7.5%) HP:0001645
9 neurological speech impairment63 occasional (7.5%) HP:0002167
10 abnormality of the eye53 Frequent (79-30%)
11 abnormality of vision53 Frequent (79-30%)
12 syncope53 Occasional (29-5%)
13 slurred speech53 Occasional (29-5%)
14 excessive daytime sleepiness53 Very frequent (99-80%)
15 abnormal rapid eye movement (rem) sleep53 Frequent (79-30%)
16 cataplexy53 Very frequent (99-80%)
17 transient global amnesia53 Very frequent (99-80%)
18 behavioral abnormality53 Occasional (29-5%)
19 somnolence53 Very frequent (99-80%)
20 insomnia53 Very frequent (99-80%)

UMLS symptoms related to Narcolepsy:


hemiplegia, sleep disturbances, hallucinations, hypnagogic, excessive daytime somnolence, sleeplessness, sluggishness

Drugs & Therapeutics for Narcolepsy

About this section

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 103)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Modafinilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 119568693-11-84236
Synonyms:
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
 
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
2
Armodafinilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1195112111-43-0
Synonyms:
 
(–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide
R-modafinil
3
Sodium oxybateapprovedPhase 4, Phase 3, Phase 2, Phase 138502-85-25360545
Synonyms:
4-Hydroxybuttersaeure natriumsalz
4-Hydroxybutyrate sodium
4-Hydroxybutyric acid monosodium salt
4-Hydroxybutyric acid sodium salt
502-85-2
ARONIS24196
Anetamin
BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT
Butanoic acid, 4-hydroxy-, monosodium salt
Butanoic acid, 4-hydroxy-, sodium salt
Butanoic acid, 4-hydroxy-, sodium salt (1:1)
Butyric acid, 4-hydroxy-, monosodium salt
Butyric acid, 4-hydroxy-, monosodium salt (8CI)
C4H7O3.Na
CHEMBL1200682
CID10412
D05866
EB 27
EINECS 207-953-3
GHB
Gamma OH
H-4040
H3635_SIGMA
HMS2091E15
Hydroxybutyric acid monosodium salt
 
LS-48077
MolPort-001-766-711
MolPort-006-717-541
NSC 84223
Natrium 4-hydroxybutyrat
OR28769
Oxybate sodium
Sodium 4-hydroxybutyrate
Sodium Oxybate [USAN]
Sodium Oxybutyrate
Sodium gamma-hydroxybutyrate
Sodium gammahydroxybutyrate
Sodium oxybate
Sodium oxybate (USAN)
Sodium-4-hydroxybutyrate
Somsanit
UNII-7G33012534
WY 3478
WY-3478
Xyrem
Xyrem (TN)
gamma-Hydroxy sodium butyrate
gamma-Hydroxybutyrate sodium
gamma-Hydroxybutyrate sodium salt
gamma-Hydroxybutyric acid sodium salt
gamma-Hydroxybutyric acid, sodium salt
4
DopamineapprovedPhase 4, Phase 2, Phase 3, Phase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
5
Gabapentinapproved, investigationalPhase 428960142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin
6
RasagilineapprovedPhase 454136236-51-63052776
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-Propargylindan-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
AC-723
AC1MHJZT
Azilect
Azilect (TN)
CHEBI:45357
 
CHEMBL887
CID3052776
D08469
DB01367
LS-186771
LS-187776
MolPort-003-850-132
NCGC00168774-01
RAS
Rasagiline (INN)
Rasagiline [INN]
UNII-003N66TS6T
ZINC19875504
rasagiline
7
Pramipexoleapproved, investigationalPhase 4139104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
 
KBio2_007476
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
8
RibavirinapprovedPhase 498436791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
9Wakefulness-Promoting AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1192
10Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
11Central Nervous System StimulantsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12132
12Cytochrome P-450 CYP3A InducersPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11101
13Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 112806
14AnalgesicsPhase 4, Phase 3, Phase 1, Phase 211287
15Psychotropic DrugsPhase 46279
16Anti-Anxiety AgentsPhase 41816
17Tranquilizing AgentsPhase 44164
18Adjuvants, AnesthesiaPhase 4, Phase 3, Phase 2, Phase 11588
19Autonomic AgentsPhase 4, Phase 2, Phase 19774
20Anesthetics, IntravenousPhase 4, Phase 3, Phase 2, Phase 12406
21Anesthetics, GeneralPhase 4, Phase 3, Phase 2, Phase 12787
22AnestheticsPhase 4, Phase 3, Phase 2, Phase 19001
23Pharmaceutical SolutionsPhase 4, Phase 37793
24VaccinesPhase 46428
25Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 117734
26Dopamine AgentsPhase 4, Phase 2, Phase 3, Phase 13759
27Protective AgentsPhase 4, Phase 1, Phase 27190
28Antimanic AgentsPhase 4790
29calcium channel blockersPhase 41940
30Excitatory Amino AcidsPhase 41297
31Antiparkinson AgentsPhase 41527
32AnticonvulsantsPhase 42620
33Excitatory Amino Acid AntagonistsPhase 41282
34Calcium, DietaryPhase 4, Phase 1, Phase 25525
35Dopamine agonistsPhase 4618
36Neuroprotective AgentsPhase 41672
37Interferon-alphaPhase 41139
38interferonsPhase 42137
39AntioxidantsPhase 42928
40
Morphineapproved, investigationalPhase 396057-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
41
Histamine PhosphateapprovedPhase 3, Phase 2103351-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
42
HistamineapprovedPhase 3, Phase 2103475614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
43
Methylphenidateapproved, investigationalPhase 2, Phase 3373113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
44
Folic Acidapproved, nutraceutical, vet_approvedPhase 3427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
45
Pyridoxineapproved, nutraceutical, vet_approvedPhase 318665-23-61054
Synonyms:
(5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate
12001-78-4
2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]
2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine
2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine
2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-methyl-4,5-dimethylol-pyridin-3-ol
2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0
3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride
3-Hydroxy-2-Picoline-4,5-dimethanol
3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride
3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride
3-Hydroxy-4,5-dimethylol-alpha-picoline
3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride
3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol
4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride
4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol
4-Deoxypyridoxine 5'-phosphate
47862_SUPELCO
5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol
5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
58-56-0
58-56-0 (HCL)
58-56-0 (hydrochloride)
65-23-6
65-23-6 (Parent)
8059-24-3
85078-23-5
AC-12024
AC-14512
AC-907/25014218
AC1L1AMH
AC1L1LMI
AC1L2XK2
AC1Q22HP
AC1Q2G66
AC1Q3F63
AI3-19016
AIDS-006784
AIDS006784
AR-1A6363
AR-1J1632
Adermin hydrochloride
Adermine
Adermine hydrochloride
Aderomine hydrochloride
Aderoxin
Aderoxine
Alestrol
BB_NC-0050
BIDD:PXR0180
BPBio1_000646
BSPBio_000586
Becilan
Beesix
Benadon
Bonasanit
C00314
C8H11NO3
CAS-58-56-0
CBDivE_015627
CCRIS 1903
CHEBI:16709
CHEBI:30961
CHEMBL1200756
CHEMBL1364
CID104817
CID1054
CID6019
CPD0-1221
Campoviton 6
Cernevit-12
D02179
D025101
D08454
DB00165
EINECS 200-386-2
EINECS 200-603-0
EINECS 232-503-8
Godabion
Gravidox
HMS1569N08
HMS2093L07
HSDB 1212
Hexa-Betalin
Hexa-Betalin (R)
Hexa-betalin (TN)
Hexabetalin
Hexabione hydrochloride
 
Hexavibex
Hexermin
Hexermine
Hexobion
Hydoxin
I02-1897
I02-2297
KST-1A8556
LS-134393
LS-187072
LS-2332
MLS001074329
MLS002153915
MolPort-002-137-856
MolPort-002-319-991
MolPort-005-933-330
NCGC00016261-01
NCGC00164317-01
NCGC00180946-01
NSC 36225
NSC36225
NSC36225 (HCL)
Nestrex
Oprea1_061614
P0561
P4722_SIAL
P5669_SIGMA
P6280_SIGMA
P8666_SIGMA
P9755_SIAL
PN
PN HCl
PYRIDOXINE HYDROCHLORIDE
PYRIDOXINE HYDROCHLORIDE, U.S.P.
Paxadon
Piridossina
Piridossina [DCIT]
Piridoxina
Piridoxina [INN-Spanish]
Prestwick0_000623
Prestwick1_000623
Prestwick2_000623
Prestwick3_000623
Prestwick_925
Pydox
Pyridipca
Pyridox
Pyridoxin
Pyridoxin hydrochloride
Pyridoxine
Pyridoxine (INN)
Pyridoxine HCl
Pyridoxine Hydrochloride (B6)
Pyridoxine [INN:BAN]
Pyridoxine chloride
Pyridoxine hydrochloride (JP15/USP)
Pyridoxine hydrochloride [USAN:JAN]
Pyridoxine hydrogen chloride
Pyridoxine monohydrochloride
Pyridoxine, hydrochloride
Pyridoxine-HCl Microencapsulated
Pyridoxinium chloride
Pyridoxinum
Pyridoxinum [INN-Latin]
Pyridoxinum hydrochloricum
Pyridoxinum hydrochloricum (Hungarian)
Pyridoxol
Pyridoxol hydrochloride
Pyridoxol, hydrochloride
Pyridoxolum
Rodex
Rodex (R)
Rodex TD
SMP2_000230
SMR000674613
SPBio_002805
STK177324
STOCK1N-08684
Spondylonal
Tex Six T.R.
TimTec1_000657
UNII-68Y4CF58BV
UNII-KV2JZ1BI6Z
Vitamin B 6
Vitamin B6
Vitamin B6-hydrochloride
Vitamin V6
Vitamin V6 (TN)
Vitamin-?B6
Vitamin-?B6 hydrochloride
Vitaped
WLN: T6NJ B1 CQ D1Q E1Q &GH
ZINC00049154
ZINC21983293
bmse000288
c1302
component of Alestrol
nchembio.93-comp1
pyridoxine
vitamin B6
46
Pyridoxalapproved, nutraceuticalPhase 318566-72-81050
Synonyms:
2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine
3-Hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde
 
3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
Piridoxal
Pyridoxal
Pyridoxaldehyde
47Analgesics, OpioidPhase 33091
48NarcoticsPhase 33486
49Vitamin B 6Phase 3186
50VitaminsPhase 35095

Interventional clinical trials:

(show top 50)    (show all 92)
idNameStatusNCT IDPhase
1Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine ChangesCompletedNCT00345800Phase 4
2Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on PrescriptionCompletedNCT00244465Phase 4
3Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDSCompletedNCT00118378Phase 4
4An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia FatigueCompletedNCT00678691Phase 4
5"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"CompletedNCT01023672Phase 4
6SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)CompletedNCT02055898Phase 4
7Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of AgeCompletedNCT01985997Phase 4
8Xyrem and Brain Dopamine in NarcolepsyRecruitingNCT02637076Phase 4
9Pain Expectations in Subjects With OsteoarthritisRecruitingNCT02155257Phase 4
10Effect of Armodafinil on Simulated DrivingNot yet recruitingNCT02468856Phase 4
11Modafinil Treatment for Sleep/Wake Disturbances in Older AdultsTerminatedNCT00626210Phase 4
12Armodafinil for Patients Starting Hepatitis C Virus TreatmentTerminatedNCT01470651Phase 4
13Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseTerminatedNCT01048229Phase 4
14Palliative Morphine With or Without Concurrent ModafinilUnknown statusNCT01766323Phase 3
15Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With NarcolepsyCompletedNCT00107796Phase 3
16Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in NarcolepsyCompletedNCT00066170Phase 3
17Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.CompletedNCT01638403Phase 3
18PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00107848Phase 3
19Trial of Xyrem® (Sodium Oxybate) for the Treatment of NarcolepsyCompletedNCT00132873Phase 3
20Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With NarcolepsyCompletedNCT00078377Phase 3
21Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep DisorderCompletedNCT00078312Phase 3
22Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic PatientsCompletedNCT00049803Phase 3
23Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive SleepinessCompletedNCT00228553Phase 3
24Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive SleepinessCompletedNCT00214968Phase 3
25Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in NarcolepsyCompletedNCT01067222Phase 3
26Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00228566Phase 3
27Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With NarcolespyCompletedNCT01067235Phase 3
28Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)CompletedNCT01789398Phase 3
29Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)CompletedNCT01800045Phase 3
30Methylphenidate to Improve Balance and Walking in MSCompletedNCT01896700Phase 2, Phase 3
31Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese PatientsCompletedNCT02478580Phase 3
32Modafinil in Cancer Related FatigueCompletedNCT01440621Phase 3
33Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in NarcolepsyRecruitingNCT02720744Phase 3
34"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"Active, not recruitingNCT02348593Phase 3
35Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)Active, not recruitingNCT01399606Phase 3
36A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With CataplexyActive, not recruitingNCT02221869Phase 3
37"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"Active, not recruitingNCT02348606Phase 3
38"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"Enrolling by invitationNCT02348632Phase 3
39A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With CataplexyNot yet recruitingNCT03030599Phase 3
40Modafinil to Treat Fatigue in Post-Polio SyndromeTerminatedNCT00067496Phase 3
41A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With NarcolepsyCompletedNCT00424931Phase 2
42A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With NarcolepsyCompletedNCT01681121Phase 2
43A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With NarcolepsyCompletedNCT01006122Phase 2
44A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime SleepinessCompletedNCT01485770Phase 2
45Clarithromycin for the Treatment of HypersomniaCompletedNCT01146600Phase 2
46Flumazenil for the Treatment of Primary HypersomniaCompletedNCT01183312Phase 1, Phase 2
47Methylphenidate and Parkinson's DiseaseCompletedNCT00359723Phase 2
48Sodium Oxybate in Schizophrenia With InsomniaCompletedNCT00594256Phase 2
49Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse HistoriesCompletedNCT00247572Phase 2
50Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant AbuseCompletedNCT00248092Phase 1, Phase 2

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS67/NDF-RT45:


Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

About this section

Genetic tests related to Narcolepsy:

id Genetic test Affiliating Genes
1 Cataplexy and Narcolepsy26

Anatomical Context for Narcolepsy

About this section

MalaCards organs/tissues related to Narcolepsy:

35
Brain, Eye, Testes, Heart, T cells, Amygdala, Skin

Animal Models for Narcolepsy or affiliated genes

About this section

MGI Mouse Phenotypes related to Narcolepsy:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538610.5ATXN3, COMT, DNMT1, HCRT, HCRTR1, HCRTR2
2MP:00036319.7ATXN3, COMT, DNMT1, HCRT, HCRTR1, HCRTR2

Publications for Narcolepsy

About this section

Articles related to Narcolepsy:

(show top 50)    (show all 799)
idTitleAuthorsYear
1
Disorders of Excessive Daytime Sleepiness Including Narcolepsy and Idiopathic Hypersomnia. (27542882)
2016
2
Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review. (26847972)
2016
3
Understanding the needs of older patients with narcolepsy. (27887886)
2016
4
A Global View on Narcolepsy - A Review Study. (27488584)
2016
5
Hypothalamic-Amygdalar-Brainstem Volume Reduction in a Patient with Narcolepsy Secondary to Diffuse Axonal Injury. (25665696)
2015
6
Narcolepsy with Cataplexy in an Elderly Woman. (25784528)
2015
7
Sleepiness and Performance Is Disproportionate in Patients with Non-Organic Hypersomnia in Comparison to Patients with Narcolepsy and Mild to Moderate Obstructive Sleep Apnoea. (25377356)
2014
8
Complete loss of F-waves during cataplectic attacks in patients with narcolepsy. (25355831)
2014
9
Dysautonomia in narcolepsy: evidence by questionnaire assessment. (25324880)
2014
10
Does autoreactivity have a role in narcolepsy? (25316012)
2014
11
HLA-DQ allele competition in narcolepsy: A comment on Tafti et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. (25325462)
2014
12
Levothyroxine Improves Subjective Sleepiness in a Euthyroid Patient With Narcolepsy without Cataplexy. (25325591)
2014
13
Childhood narcolepsy with cataplexy: a newly reported phenotype of an old disease? (23831236)
2013
14
HLA-DQ association and allele competition in Chinese narcolepsy. (22862152)
2012
15
Use of PCR with sequence-specific primers for high-resolution human leukocyte antigen typing of patients with narcolepsy. (22259780)
2012
16
Narcolepsy: neural mechanisms of sleepiness and cataplexy. (22956821)
2012
17
The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. (23026503)
2012
18
Narcolepsy presenting as schizophrenia: a literature review and two case reports. (21637632)
2011
19
Cerebrospinal fluid hypocretin 1 deficiency, overweight, and metabolic dysregulation in patients with narcolepsy. (22171205)
2011
20
Waking up to narcolepsy. (21866561)
2011
21
Control of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsy. (22205591)
2011
22
Anesthetic management of a patient with narcolepsy. (21448767)
2011
23
Narcolepsy-cataplexy induced by a cow milk oral immunotherapy protocol? (21757404)
2011
24
Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. (21930661)
2011
25
Narcolepsy, idiopathic hypersomnolence and related conditions. (21902087)
2011
26
Clinical features of childhood narcolepsy. Can cataplexy be foretold? (21345702)
2011
27
Autonomic response to periodic leg movements during sleep in narcolepsy-cataplexy. (21286243)
2011
28
Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. (21102987)
2010
29
Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy. (21210337)
2010
30
Restless legs syndrome associated with narcolepsy and somnambulism. (19703790)
2010
31
Narcolepsy and Behcet's disease: report of a Chinese-Taiwanese case. (20022557)
2010
32
The economic consequences of narcolepsy. (19960645)
2009
33
Agenesis of the corpus callosum associated with narcolepsy-cataplexy. (18276185)
2009
34
Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. (18274271)
2008
35
Searching for a marker of REM sleep behavior disorder: submentalis muscle EMG amplitude analysis during sleep in patients with narcolepsy/cataplexy. (18853938)
2008
36
Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). (18718966)
2008
37
Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. (18769859)
2008
38
Identification of differentially expressed genes in blood cells of narcolepsy patients. (17702266)
2007
39
Treatment of narcolepsy with cataplexy. (17398305)
2007
40
Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy. (17187965)
2007
41
Anaesthetic management and perioperative monitoring of a patient with narcolepsy. (17977105)
2007
42
Reduced hypothalamic gray matter in narcolepsy with cataplexy. (17187022)
2006
43
Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. (16006155)
2005
44
The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. (15320603)
2004
45
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. (12374492)
2002
46
Low cerebrospinal fluid hypocretin levels found in familial narcolepsy. (14592396)
2001
47
Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. (11723284)
2001
48
Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. (11435802)
2001
49
Narcolepsy: a key role for hypocretins (orexins) (10481905)
1999
50
The narcolepsy-associated DRw15,DQw6,Dw2 haplotype has no unique HLA-DQA or -DQB restriction fragments and does not extend to the HLA-DP subregion. (1973684)
1990

Variations for Narcolepsy

About this section

Copy number variations for Narcolepsy from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
117730935514702955255377InsertionHCRTR2Narcolepsy

Expression for genes affiliated with Narcolepsy

About this section
Search GEO for disease gene expression data for Narcolepsy.

Pathways for genes affiliated with Narcolepsy

About this section

GO Terms for genes affiliated with Narcolepsy

About this section

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class II protein complexGO:004261310.7HLA-DQA1, HLA-DQB1, HLA-DRB1
2integral component of lumenal side of endoplasmic reticulum membraneGO:007155610.7HLA-DQA1, HLA-DQB1, HLA-DRB1
3ER to Golgi transport vesicle membraneGO:001250710.6HLA-DQA1, HLA-DQB1, HLA-DRB1
4clathrin-coated endocytic vesicle membraneGO:003066910.6HLA-DQA1, HLA-DQB1, HLA-DRB1
5trans-Golgi network membraneGO:003258810.3HLA-DQA1, HLA-DQB1, HLA-DRB1
6endocytic vesicle membraneGO:003066610.3HLA-DQA1, HLA-DQB1, HLA-DRB1
7transport vesicle membraneGO:003065810.2HLA-DQA1, HLA-DQB1, HLA-DRB1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of glucose importGO:004632510.8LEP, TNF
2leukocyte tethering or rollingGO:005090110.8LEP, TNF
3response to peptideGO:190165210.8HCRTR1, HCRTR2
4interferon-gamma-mediated signaling pathwayGO:006033310.7HLA-DQA1, HLA-DQB1, HLA-DRB1
5negative regulation of lipid storageGO:001088810.7LEP, TNF
6neuropeptide signaling pathwayGO:000721810.6HCRT, HCRTR1, HCRTR2
7phospholipase C-activating G-protein coupled receptor signaling pathwayGO:000720010.6HCRT, HCRTR2, P2RY11
8antigen processing and presentation of exogenous peptide antigen via MHC class IIGO:001988610.3HLA-DQA1, HLA-DQB1, HLA-DRB1
9regulation of circadian sleep/wake cycle, sleepGO:004518710.3HCRTR1, HCRTR2
10chemical synaptic transmissionGO:000726810.1ATXN3, HCRT, HCRTR1, HCRTR2
11T cell costimulationGO:003129510.0HLA-DQA1, HLA-DQB1, HLA-DRB1

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1orexin receptor activityGO:001649910.8HCRTR1, HCRTR2
2MHC class II receptor activityGO:003239510.7HLA-DQA1, HLA-DQB1
3neuropeptide receptor activityGO:000818810.6HCRTR1, HCRTR2
4peptide antigen bindingGO:004260510.3HLA-DQA1, HLA-DQB1, HLA-DRB1

Sources for Narcolepsy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet